Belite Bio, Inc
BLTE
Rank in Stocks
#3146
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Share Price
$143.80
Last synced: 2026-10-16
Market Cap
$5.74B
Change (1 day)
-5.78%
Change (1 year)
63.95%
Country
US
Trade Belite Bio, Inc (BLTE)
Category
Healthcare
Earnings for Belite Bio, Inc (BLTE)
Earnings in Jun 2026 TTM: $-102.31M
According to Belite Bio, Inc latest financial reports the company's current earnings are $-102.31M. In 2023 the company made an earning of $-31.62M, a decrease compared to its 2022 earnings that were of $-12.65M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Belite Bio, Inc from 2020 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-102.31M | 183.11% |
| 2024 | $-36.14M | 14.28% |
| 2023 | $-31.62M | 150.02% |
| 2022 | $-12.65M | 30.85% |
| 2021 | $-9.67M | 68.05% |
| 2020 | $-5.75M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -5,255.85% |
US
|
|
| $-3.09B | 2,917.33% |
US
|
|
| $-4.02B | 3,825.56% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -2,006.63% |
NL
|
